American Financial Outperforms Industry in a Year: Time to Hold?

American Financial Group’s second-quarter 2026 net written premiums rose 6%, its Specialty combined ratio improved to 91.5% from 93.1% a year earlier, and first-half underwriting profit increased 44%. P&C investment income rose 23% year over year to a record quarterly level; AFG also raised its annual dividend 10.2% and returned nearly $100 million to shareholders during the quarter. Zacks estimates 2026 EPS growth of 19.4%, but rates that shares a Hold; its six-analyst average target of $155.83 implies 12.85% upside from the last close.

Analysis

AFG’s earnings leverage is increasingly split between underwriting discipline and investment income, so the key question is whether both can hold up as the P&C cycle matures. Renewal pricing in selected casualty lines may cushion softer markets elsewhere, but elevated pricing can also invite competition; if rate increases fall below claims-cost trends, today’s underwriting improvement could reverse with a lag. Commercial auto and excess-liability severity and reserve development deserve particular scrutiny, not just written-premium growth.

The investment-income tailwind is less one-way than the headline earnings case implies: lower reinvestment yields would gradually reduce fixed-income carry, while alternative returns can be volatile. Capital flexibility lowers financing risk, but does not insulate earnings from catastrophe losses, reserve surprises, or weaker alternatives.

Near term, relative strength may attract momentum flows, but technicals and analyst targets are not evidence of incremental earnings power. Over 1–3 months, quarterly renewal-rate disclosures, the Specialty combined ratio, reserve releases/development, and alternative-investment returns are the decisive catalysts. Over 6–18 months, the test is whether niche-line pricing remains disciplined as competition returns. The contrarian risk is that investors extrapolate unusually favorable underwriting and investment conditions together.

Key Decisions for Investors

• Maintain or build a measured AFG long on weakness rather than chase strength; scale only if renewal pricing remains firm and the Specialty combined ratio stays controlled. This offers participation in earnings and capital returns, with the main downside being a simultaneous turn in pricing and claims costs.
• For the next earnings release, track casualty severity and reserve development alongside premium growth. Treat deterioration in those measures or a clear combined-ratio reversal as a thesis-break signal, even if reported revenue continues to grow.
• Do not short ACGL, WRB, or KNSL solely because their shares lagged AFG in the cited period; valuation and earnings revisions are missing. Consider a peer-relative position only after comparing current multiples, underwriting trends, and estimate revisions.
• Monitor fixed-income reinvestment yields and alternative-investment results. If investment income weakens while underwriting margins also compress, reduce exposure; if both persist, the market may be underestimating earnings durability.